Our research areas of focus
GSK currently has 14 oncology assets in clinical development, and we are pleased to be sharing presentations at ASH that have the potential to demonstrate meaningful improvements in outcomes for patients.
As a leader in oncology research and development, we have advanced our innovative pipeline by focusing on science related to the immune system, the use of human genetics and cutting-edge technologies that will advance the next wave of cancer therapies.
Meet the Experts
GSK at ASH
GSK at ASH 2020
At ASH, we are proud to share updates from 13 studies and analyses, including new data from our DREAMM clinical trial program.
Our presentations at ASH 2020
Click here for more information regarding our participation in the virtual ASH Conference program